北京大学肿瘤医院黑色素瘤与肉瘤内科副主任，主任医师，教授，博士生导师，医学博士。教育部新世纪优秀人才, 北京市医院管理局“登峰”人才计划，北京市科技新星，北京市优秀青年拔尖人才。目前担任国家癌症中心国家肿瘤质控中心黑色素瘤专委会副主任委员，中国临床肿瘤学会黑色素瘤专家委员会副主任委员，中国临床肿瘤学会神经肿瘤专家委员会副主任委员，中国抗癌协会肉瘤专委会肿瘤多学科学组副组长，中国临床肿瘤学会免疫治疗…

北京大学肿瘤医院黑色素瘤与肉瘤内科副主任，主任医师，教授，博士生导师，医学博士。教育部新世纪优秀人才, 北京市医院管理局“登峰”人才计划，北京市科技新星，北京市优秀青年拔尖人才。目前担任国家癌症中心国家肿瘤质控中心黑色素瘤专委会副主任委员，中国临床肿瘤学会黑色素瘤专家委员会副主任委员，中国临床肿瘤学会神经肿瘤专家委员会副主任委员，中国抗癌协会肉瘤专委会肿瘤多学科学组副组长，中国临床肿瘤学会免疫治疗专委会常委，亚洲黑色素瘤联盟学术秘书等职务。

主要从事黑色素瘤、皮肤肿瘤、泌尿肿瘤的临床综合治疗和转化医学研究，主持国家级、省部级科研项目6项，发表SCI论文50余篇，以第一或通讯作者发表SCI论文20余篇，总影响因子近300分，单篇最高他引次数超400次。作为执笔人参编卫健委《黑色素瘤诊疗规范》、《中国肿瘤整合诊治指南》黑色素瘤分册、《CSCO黑色素瘤诊疗指南》。作为主要骨干参与黑色素瘤CFDA注册临床研究20余项，并促成4个黑色素瘤新药获得国家药监局批准上市。其研究成果改写了2个国际及和3个国内指南/规范。

获得省部级科技二等奖1项，CSCO科技奖2项，中华医学会科技奖1项。

发表论文

1. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Mao L, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Diede SJ, Dai H, Niu C, Li J, Guo J. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Front Immunol. 2022 Oct 11;13:882471.

2. Wei X, Chen Y, Yao H, Wu D, Li H, Zhang R, Chi Z, Cui C, Bai X, Mao L, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Lian B, Kong Y, Dai J, Tang B, Wang X, Gershenwald JE, Balch CM, Guo J, Si L. Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. J Am Acad Dermatol. 2022 Sep 6:S0190-9622(22)02627-5.

3. Liu J, Tan Z, Xue R, Fan Z, Bai C, Li S, Gao T, Zhang L, Fang Z, Si L. The efficacy of (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients. Ann Transl Med. 2022;10(2):95.

4. Wei X, Wu D, Chen Y, Li H, Zhang R, Yao H, Chi Z, Cui C, Bai X, Mao L, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Lian B, Kong Y, Dai J, Tang B, Wang X, Guo J, Si L. Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study. Br J Dermatol. 2022;186(6):977-87.

5. Mao L, Guo J, Zhu L, Jiang Y, Yan W, Zhang J, Hui AM, Yang Y, Diao L, Tan Y, Zhao H, Jiang Y, Wu Z, Si L. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2022;175:125-35.

6. Mao L, Fang M, Chen Y, Wei X, Cao J, Lin J, Zhang P, Chen L, Cao X, Chen Y, Guo J, Si L. Atezolizumab Plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: a Multicenter, Open-label, Single-arm Phase 2 Study. Clin Cancer Res. 2022 Nov 1;28(21):4642-4648.

7. Zhang S, Zhang J, Guo J, Si L, Bai X. Evolving Treatment Approaches to Mucosal Melanoma. Curr Oncol Rep. 2022;24(10):1261-71.

8. Tang L, Wei X, Li C, Dai J, Bai X, Mao L, Chi Z, Cui C, Lian B, Tang B, Du Y, Wang X, Lai Y, Sheng X, Yan X, Li S, Zhou L, Kong Y, Li Z, Si L, Guo J. Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma. Front Oncol. 2022;12:895672.

9. Xu C, Si L, Wang W, Li Z, Song Z, Wang Q, Liu A, Yu J, Fang W, Zhong W, Wang Z, Zhang Y, Liu J, Zhang S, Cai X, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Chen Y, Yuan J, Wang F, Jiang Z, Lin G, Pu X, Lin R, Liu W, Rao C, Lv D, Yu Z, Lei L, Li X, Tang C, Zhou C, Zhang J, Xue J, Guo H, Chu Q, Meng R, Wu J, Zhang R, Hu X, Zhou J, Zhu Z, Li Y, Qiu H, Xia F, Lu Y, Chen X, Ge R, Dai E, Han Y, Pan W, Luo J, Jia H, Dong X, Pang F, Wang K, Wang L, Zhu Y, Xie Y, Lin X, Cai J, Wei J, Lan F, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Wei Q, Kang J, Zhang J, Zhang C, Yu G, Ou J, Shi L, Li Z, Liu Z, Liu J, Yang N, Wu L, Wang H, Jin G, Yang L, Wang G, Fang M, Fang Y, Li Y, Wang X, Zhang Y, Ma S, Wang B, Zhang X, Song Y, Lu Y. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China. Thorac Cancer. 2022.

10. Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021;12:680407.

11. Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Bai X, Li S, Guo J, Cui C, Si L. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Front Immunol. 2021;12:691032.

12. Mao L, Ding Y, Bai X, Sheng X, Dai J, Chi Z, Cui C, Kong Y, Fan Y, Xu Y, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Guo J, Zhang X, Si L. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front Oncol. 2021;11:720044.

13. Bai X, Dai J, Li C, Cui C, Mao L, Wei X, Sheng X, Chi Z, Yan X, Tang B, Lian B, Wang X, Zhou L, Li S, Kong Y, Qi Z, Xu H, Duan R, Guo J, Si L. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials. Front Oncol. 2021;11:639085.

14. Li H, Yang L, Lai Y, Wang X, Han X, Liu S, Wang D, Li X, Hu N, Kong Y, Si L, Li Z. Genetic alteration of Chinese patients with rectal mucosal melanoma. BMC Cancer. 2021 May 27;21(1):623. IF=3.15

15. Mao L, Dai J, Cao Y, Bai X, Sheng X, Chi Z, Cui C, Kong Y, Zhang Y, Wu L, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Qi Z, Si L, Guo J. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 May;148:297-306.

16. Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020;135:31-8.

17. Wei X, Wu D, Li H, Zhang R, Chen Y, Yao H, Chi Z, Sheng X, Cui C, Bai X, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Mao L, Lian B, Kong Y, Dai J, Tang B, Yan X, Wang X, Li S, Zhou L, Balch CM, Si L, Guo J. The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. Ann Surg Oncol. 2020;27(9):3478-85.

18. Wei X, Si L, Guo J. ASO Author Reflections: Primary Site Should Be Regarded as One Important Factor for Risk Stratification in Acral Melanoma. Ann Surg Oncol. 2020 Sep;27(9):3486-3487.

19. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Mao L, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Diede SJ, Zhou Y, Ge J, Li J, Wu H, Guo J. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Transl Oncol. 2019;12(6):828-35.

20. Wei X, Mao L, Chi Z, Sheng X, Cui C, Kong Y, Dai J, Wang X, Li S, Tang B, Lian B, Yan X, Bai X, Zhou L, Guo J, Si L. Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. Oncol Res. 2019;27(4):495-501.

21. Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo J. Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer. 2018;18(1):520.

22. Yu Z, Si L. Immunotherapy of patients with metastatic melanoma. Chin Clin Oncol. 2017;6(2):20.

23. Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clin Cancer Res. 2017;23(20):6120-7.

24. Si L, Wang X, Guo J. Genotyping of mucosal melanoma. Chin Clin Oncol. 2014;3(3):34.

25. Si L, Guo J. C-kit-mutated melanomas: the Chinese experience. Curr Opin Oncol. 2013;25(2):160-5.

26. Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J. Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol. 2012;30(4):e37-40.

27. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48(1):94-100.

28. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-9.

29. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients. Eur J Cancer. 2011;47(10):1498-503.